Through TRAP staining, we found that osteoclast activity in DM group was significantly increased, and PPARβ/δ agonist treatment could reduce the activation of osteoclasts under diabetic condition (Figures 2B,C). The gene discussed is ACP5; the disease is diabetes mellitus.